As of March, 6 Collegium Pharmaceutical, Inc. (COLL) EPS Estimated At $-0.36

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Corporate Logo

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s earnings report is awaited by WallStreet on March, 6, according to RTT. Analysts forecast 33.33 % diference or $-0.36 from the $-0.54 EPS from 2018. Wall Street now forecasts -28.00 % EPS growth despite Collegium Pharmaceutical, Inc. previous quarter’s EPS of $-0.50. COLL is hitting $13.87 during the last trading session, after decreased 3.61%.Collegium Pharmaceutical, Inc. has 478,532 shares volume, 10.97% up from normal. COLL is uptrending and has moved 4.69% since February 12, 2018. COLL outperformed by 4.69% the S&P 500.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The firm is worth $461.14 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Last it reported negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news released briefly go to:,,, or The titles are as follows: “Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal – GlobeNewswire” released on November 21, 2016, “Collegium Pharmaceuticals – Xtampza Sales Ramp-Up Disappoints – Seeking Alpha” on May 12, 2017, “Collegium Is Worth Keeping An Eye On – Seeking Alpha” with a publish date: April 29, 2016, “Collegium Receives FDA Approval for sNDA for Xtampza® ER – GlobeNewswire” and the last “Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER – GlobeNewswire” with publication date: October 29, 2018.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.